{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:18:53Z","timestamp":1760059133592,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Aim: Fibrillary glomerulonephritis (FGN) is a rare glomerular disease characterized by non-amyloid fibrillary deposits in the glomeruli and positive staining for DNAJB9. There is currently no treatment of choice, and the poor prognosis highlights the need for further research. We aimed to investigate the clinical and pathological characteristics and outcomes of FGN patients from a tertiary nephrology center. Methods: A retrospective cohort study of eleven patients diagnosed with FGN between 2016 and 2025, based on kidney biopsy and DNAJB9 positivity, was used. Partial response was defined as a \u226550% reduction in proteinuria with stable renal function. Results: At diagnosis, nine patients had nephrotic-range proteinuria, and eight had microscopic hematuria. Mean serum creatinine was 1.6 mg\/dL, and mean proteinuria was 3.78 g\/24 h. Comorbidities included SLE (n = 1), sarcoidosis (n = 1), and lung cancer (n = 1). The most common histological pattern was mesangial proliferative (n = 6). DNAJB9 staining was positive in five patients. All patients received RAAS blockade and immunosuppression (e.g., corticosteroids, rituximab). Partial response occurred in 73% with a median follow-up of 24 months, with 80% showing &gt;50% proteinuria reduction. One patient died during follow-up; no patients progressed to ESRD or required dialysis. Conclusions: FGN is clinically diverse and lacks a standard treatment. The small sample size limits generalizability.<\/jats:p>","DOI":"10.3390\/jcm14113709","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T02:50:05Z","timestamp":1748227805000},"page":"3709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Challenges and New Era in Fibrillary Glomerulonephritis with the Introduction of DNAJB9: Experience from a Tertiary Nephrology Center"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0448-6549","authenticated-orcid":false,"given":"Tsielestina","family":"Poulli","sequence":"first","affiliation":[{"name":"Department of Nephrology, General Hospital of Athens \u201cGeorgios Gennimatas\u201d, 154 Mesogeion Avenue, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Liaveri","sequence":"additional","affiliation":[{"name":"Department of Nephrology, General Hospital of Athens \u201cGeorgios Gennimatas\u201d, 154 Mesogeion Avenue, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Liapis","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Daoudaki","sequence":"additional","affiliation":[{"name":"Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, University Campus, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadni","family":"Fouza","sequence":"additional","affiliation":[{"name":"Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, University Campus, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"},{"name":"1st Nephrology Clinic, Hippokration General Hospital of Thessaloniki, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-9863","authenticated-orcid":false,"given":"Maria","family":"Stangou","sequence":"additional","affiliation":[{"name":"1st Nephrology Clinic, Hippokration General Hospital of Thessaloniki, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Moustakas","sequence":"additional","affiliation":[{"name":"Department of Nephrology, General Hospital of Athens \u201cGeorgios Gennimatas\u201d, 154 Mesogeion Avenue, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/ki.1987.66","article-title":"Fibrillary glomerulonephritis: An entity with unusual immunofluorescence features","volume":"31","author":"Alpers","year":"1987","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1046\/j.1523-1755.2003.00853.x","article-title":"Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features","volume":"63","author":"Rosenstock","year":"2003","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ekir.2019.04.013","article-title":"Fibrillary Glomerulonephritis: An Update","volume":"4","author":"Rosenstock","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2215\/CJN.10871016","article-title":"Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986\u20132015","volume":"12","author":"Hogan","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2215\/CJN.08300910","article-title":"Fibrillary glomerulonephritis: A report of 66 cases from a single institution","volume":"6","author":"Nasr","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.clinre.2016.07.002","article-title":"Paraneoplastic fibrillary glomerulonephritis associated with intrahepatic cholangiocarcinoma: When diagnosis of a rare kidney disease leads to successful hepatic cancer treatment","volume":"41","author":"Normand","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2215\/CJN.03870319","article-title":"Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort","volume":"6","author":"Andeen","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000455390","article-title":"Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis","volume":"45","author":"Jobson","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5414\/CN109215","article-title":"Fibrillary glomerulonephritis in an HIV patient without concurrent hepatitis C infection: Case report and review of the literature","volume":"89","author":"Zhang","year":"2018","journal-title":"Clin. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/j.ajkd.2013.03.031","article-title":"Long-term kidney disease outcomes in fibrillary glomerulonephritis: A case series of 27 patients","volume":"62","author":"Javaugue","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e26022","DOI":"10.1097\/MD.0000000000026022","article-title":"Clinicopathologic features and treatment outcomes of patients with fibrillary glomerulonephritis: A case series","volume":"100","author":"Marinaki","year":"2021","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1681\/ASN.2017050566","article-title":"DnaJ Homolog Subfamily B Member 9 Is a Putative Autoantigen in Fibrillary GN","volume":"29","author":"Andeen","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1681\/ASN.2017030306","article-title":"DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN","volume":"29","author":"Dasari","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ekir.2017.07.017","article-title":"DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis","volume":"3","author":"Nasr","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40620-020-00783-4","article-title":"Clinicopathological characteristics and outcome of patients with fibrillary glomerulonephritis: DNAJB9 is a valuable histologic marker","volume":"34","author":"Liang","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gambella, A., Pitino, C., Barreca, A., Nocifora, A., Giarin, M.M., Bertero, L., Biancone, L., Roccatello, D., Papotti, M., and Cassoni, P. (2022). DNAJB9 Is a Reliable Immunohistochemical Marker of Fibrillary Glomerulonephritis: Evaluation of Diagnostic Efficacy in a Large Series of Kidney Biopsies. Biomedicines, 27.","DOI":"10.3390\/biomedicines10092102"},{"key":"ref_17","first-page":"9","article-title":"The function of the co-chaperone ERdj4 in diverse (patho-)physiological conditions","volume":"79","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"KDIGO Glomerular Diseases Work Group (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int., 100, S1\u2013S276.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.kint.2020.02.025","article-title":"DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients","volume":"98","author":"Said","year":"2020","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Da, Y., Goh, G.H., Lau, T., Chng, W.J., and Soekojo, C.Y. (2022). Fibrillary glomerulonephritis and monoclonal gammopathy: Potential diagnostic challenges. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.880923"},{"key":"ref_21","first-page":"956","article-title":"Fibrillary glomerulonephritis: An update. The Authors Reply","volume":"5","author":"Andeen","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/oxfordjournals.ndt.a027409","article-title":"Clinical features, predictors of disease progression and results of renal transplantation in fibrillary\/immunotactoid glomerulopathy","volume":"11","author":"Pronovost","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.akdh.2024.03.006","article-title":"Updates on the Diagnosis and Management of Fibrillary Glomerulonephritis","volume":"31","author":"Attieh","year":"2024","journal-title":"Adv. Kidney Dis. Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/ndt\/gfaa065","article-title":"Treatment of fibrillary glomerulonephritis with rituximab: A 12-month pilot study","volume":"36","author":"Erickson","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_25","first-page":"e47862","article-title":"DNAJB9 Fibrillary Glomerulonephritis with Membranous-like Pattern: A Case-Based Literature Review","volume":"28","author":"Sabanis","year":"2023","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.molcel.2016.07.012","article-title":"Members of the Hsp70 Family Recognize distinct types of sequences to execute ER quality control","volume":"1","author":"Behnke","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.kint.2019.01.024","article-title":"Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients","volume":"95","author":"Nasr","year":"2019","journal-title":"Kidney Int."},{"key":"ref_28","first-page":"711","article-title":"Fingerprint and other organised deposits in lupus nephritis","volume":"112","author":"Hvala","year":"2000","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00467-009-1168-z","article-title":"Fibrillary glomerulonephritis and renal failure in a child with systemic lupus erythematosus","volume":"24","author":"Menon","year":"2009","journal-title":"Pediatr. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11255-011-0073-0","article-title":"Fibrillary glomerulonephritis in a patient with systemic lupus erythematosus: A rare association","volume":"45","author":"Bhat","year":"2013","journal-title":"Int. Urol. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e253388","DOI":"10.1136\/bcr-2022-253388","article-title":"Fibrillar glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis","volume":"16","author":"Whelband","year":"2023","journal-title":"BMJ Case Rep."},{"key":"ref_32","first-page":"65","article-title":"Clinicopathological study of glomerular diseases associated with sarcoidosis: A multicenter study","volume":"30","author":"Joly","year":"2013","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:40:17Z","timestamp":1760031617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14113709"],"URL":"https:\/\/doi.org\/10.3390\/jcm14113709","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,5,26]]}}}